PEGS, Barcelona, Spain
November 2, 2021
Assays for protein quantification and purity assessment are a routine and critical part of any antibody discovery and development workflow, including for bispecific antibody (bsAb) formats. When developing bsAbs using their DuoBody® platform, Genmab performs such assays on a regular basis following batch production and purification of lead parent molecules and post Fab-arm exchange. Previously, Genmab analyzed their protein production assays using a combination of instrument software and Excel macros, leading to a lack of data traceability and high maintenance burden. Genedata Screener® was implemented to automate the analysis of these highly standard assays, including A280 quantification, Octet quantification, and hydrophobic interaction chromatography (HIC)/cation exchange chromatography (CIEX). Furthermore, Screener integrated with Genedata Biologics® to form an assay cascade in which results from the A280 assay were seamlessly reported, then later retrieved along with other key molecule properties for result calculation during analysis of the same protein batches using different assays.